1373 FIRST REPORT OF SVR12 FOR A NS5A REPLICATION COMPLEX INHIBITOR BMS-790052 IN COMBINATION WITH PEG-IFNa-2A AND RBV: PHASE 2A TRIAL IN TREATMENT-NAIVE HCV-GENOTYPE-1 SUBJECTS
@article{Pol20111373FR,
title={1373 FIRST REPORT OF SVR12 FOR A NS5A REPLICATION COMPLEX INHIBITOR BMS-790052 IN COMBINATION WITH PEG-IFNa-2A AND RBV: PHASE 2A TRIAL IN TREATMENT-NAIVE HCV-GENOTYPE-1 SUBJECTS},
author={S. Pol and R. Ghalib and V. Rustgi and C. Martorell and G. Everson and H. Tatum and C. H{\'e}zode and J. Lim and J. Bronowicki and G. Abrams and N. Br{\"a}u and D. W. Morris and P. Thuluvath and R. Reindollar and P. Yin and U. Diva and R. Hindes and F. Mcphee and M. Gao and A. Thiry and S. Schnittman and E. Hughes},
journal={Journal of Hepatology},
year={2011},
volume={54}
}Topics from this paper
27 Citations
Future perspectives: towards interferon-free regimens for HCV.
- Medicine
- Antiviral therapy
- 2012
- 15
- Highly Influenced
Prevention of hepatitis C virus infection and liver cancer.
- Medicine
- Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer
- 2014
- 15
Current and emerging antiviral treatments for hepatitis C infection
- Medicine
- British journal of clinical pharmacology
- 2013
- 46
Direct-acting antiviral agents for hepatitis C virus infection.
- Medicine
- Annual review of pharmacology and toxicology
- 2013
- 80
How to optimize HCV therapy in genotype 1 patients with cirrhosis
- Medicine
- Liver international : official journal of the International Association for the Study of the Liver
- 2013
- 32
Resistance analysis of hepatitis C virus genotype 1 prior treatment null responders receiving daclatasvir and asunaprevir
- Medicine
- Hepatology
- 2013
- 127
Synthetic anti-lipopolysaccharide peptides and hepatitis C virus infection
- Biology, Medicine
- Expert opinion on investigational drugs
- 2013
- 1